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     In the last decade, along with the problem of nosocomial infections, multidrug-resistant bacteria in 
community and hospitals have soared. High frequencies of multidrug-resistant bacteria have been grouped 
under the acronym ESKAPE: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. The ESKAPE pathogens are 
responsible for the majority of nosocomial infections and capable of 'escaping' the biocidal action of 
antimicrobial agents. The objective of this review is to consider the clinical importance of emerging of 
ESKAPE pathogens in nosocomial infections to prepare feasible data about tracing and treatment of 
infection related to ESKAPE pathogens that may be beneficial to clinicians at the bedhead. It can be said 
that healthcare-associated, community-acquired, and nosocomial infections should be clearly considered 
annually. The awareness of residential antimicrobial resistance can support selecting a convenient empirical 
therapeutic diet in diseases due to ESKAPE pathogens. 
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INTRODUCTION 
     One of the most important health concerns is 
antimicrobial resistance. In the last decade along 
with the problem of nosocomial infections, the 
presence of multidrug-resistant bacteria in 
community and hospitals has been increased. 
High frequencies of multidrug-resistant bacteria 
have been grouped under the acronym ESKAPE: 
Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacter spp. 
(1-3). The ESKAPE pathogens are responsible for 
the majority of nosocomial infections and capable 
of 'escaping' the biocidal action of antimicrobial 
agents. [2, 4, 5] Antibiotics have greatly 
influenced life on earth since 1930s. Four decades 
of extravagant antibiotic utilization had 
practicable selective pressure on high-level 
antimicrobial resistance and multiple-drug 
resistance (MDR) antibiotics caused threats to the 
end of the “antibiotic period”. [2- 5] The common 
response to rising resistance has been followed by 
the proper preface of a novel class of antibiotics 
production. In a fundamental decrease in new 
antimicrobials production, generation rate 
currently fails to keep rise in resistance 
worldwide. [7]It has been predicted that the lack 
of proper combination of antibiotics would have 
miscellaneous ramifications on universal criteria, 
public health, security and international political 
consistency. [8]Health authorities, such as the 
Infectious Diseases Society of America (IDSA), 
the European Centre for Disease Prevention and 
Control (ECDC) and the World Health 
Organization (WHO), have enhanced industrial 
incentives in an attempt to arouse research into 
novel antimicrobial combination, ameliorate 
antibiotic surveillance force to cover the 
remaining therapeutic options to physicians and 
encourage a focused, concerted endeavor against 
life-threatening infections due to multidrug-
resistant (MDR) and pandrug-resistant Gram-
negative bacteria. [4, 8-12]Empiric antibiotic 
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therapy can ameliorate patients with infections 
due to these microorganisms. [13, 14] Yet, most 
studies indicated that improper antimicrobial 
therapy can be decreased through  using an 
empiric combination therapy. However the 
combination therapy consist the potential for a 
synergistic consequences and detention of 
resistance appearance. [15- 18]Synergy is a 
microbiological description well-known in in-
vitro study. Prohibition of subsequent resistance 
in some pathogens such as Pseudomonas 
aeruginosa can be postponed by the use of the  in-
vitro combinations of levofloxacin and imipenem 
(IMP).[19, 20]No clinical studies on combination 
therapy in infections due to Gram-negative 
bacteria have formally tested or demonstrated this 
hypothesis. [21]Combination diets that contain 
aminoglycosides have been shown to develop for 
higher toxicity rates in patient such as 
nephrotoxicity than monotherapy diet. In patients 
with sepsis due to Gram-negative who are often 
volume depleted, metabolic acidosis is present 
and they are faced with other nephrotoxic agents. 
[22] 
Combination therapy is mostly used in the clinical 
workout and depends on the orientation of 
infectious disease doctors, combining the  
antimicrobial treatment, especially over 
tuberculosis, HIV infection, brucellosis, C. 
difficile-associated colitis, enterococcal 
endocarditis, and Helicobacter pylori infection. 
[23]The objective of this review is to consider the 
clinical importance of emerging ESKAPE 
pathogens in nosocomial infections to prepare the 
feasible data on tracing and treatment of 
infections related to ESKAPE pathogens .
Enterococcus faecium 
     Enterococci are gram positive cocci that 
distribute extensively in nature such as grounds, 
water, plants, and food, and are normal flora of 
human and animal enteric tract. [24] Due to their 
capability to survive under contrary 
environmental conditions, Enterococci have an 
accepted function in meat and dairy products and 
is used as probiotics in food and biological 
maintainer. [25, 26] Enterococci are opportunistic 
bacteria which cause severe infectious diseases. 
[27]Some strains of this genus are resistance to a 
broad number of antimicrobial drugs; these strains 
show inherent and acquired antimicrobial 
resistance. [28] The resistance characteristics can 
transfer intragenus horizontally or 
phylogenetically between related genus. 
[29]Enterococci can obtain resistance to 
erythromycin, glycopeptides, tetracycline, 
vancomycin (vancomycin - resistant enterococci; 
VRE), aminoglycosides (high-level resistance; 
HLR), gentamicin (high-level resistance 
gentamicin; HLGR) and streptomycin (high-level 
resistance streptomycin; HLSR. [30]In Europe, 
HLR enterococci have been recovered from dairy 
and meat products as well as strains with multiple 
antimicrobial resistances, containing vancomycin. 
[31-33]Various reports have demonstrated that 
Enterococcus faecalis and Enterococcus faecium 
can cause several infections including septicemia, 
urinary tract infections, endocarditis, bacteremia, 
wound infections, meningitis, and neonatal sepsis 
[34-36]. Moreover, the simultaneous emergence 
of VRE and HLAR is a persisting clinical 
problem in health care facilities. [37-39] 
There are nine vancomycin resistance genes 
including van A, B, C, D, E, G, L, M, and van N 
in Enterococci. Van A is the most common type 
worldwide [41-45]  mainly related to vancomycin 
resistant Enterococcus faecium, allowing a great 
rate of vancomycin and teicoplanin resistance 
[46] and Van B causes a high degree of 
vancomycin resistance, yet  susceptible to other 
glycopeptides such as teicoplanin [47,48]. 
Nosocomial infections due to Enterococci have 
been introduced extensively all over the world. 
The Significant reason for long-term permanence 
of enterococci in the hospital is their inherent 
resistance to multiple antibiotics generally used 
and the resistance to novel generation of 
antibiotics via either gene mutation or 
transmission of plasmids and transposons. 
Moreover, enterococci can transfer the 
vancomycin resistance genes to another species as 
well as to other genus. Also, the transmission of 
vancomycin resistant gene from Enterococcus to 
S.aureus has been detected in the laboratory. The 
emergence of vancomycin- intermediate (VISA) 
and vancomycin-resistant Staphylococcus aureus 
(VRSA) can produce important problems to the   
 
Journal of Paramedical Sciences (JPS)                Summer2016 Vol 7, No3. ISSN 2008-4978 
45 
 
treatment of S.aureus. since vancomycin has been 
considered as a drug of choice for treatment of 
enterococcal and MRSA infections.Enterococcus 
faecium also causes nosocomial infections. 
Emergence of vancomycin resistant strains has 
been related to further charge on the patients, 
physicians and health setting. Appropriate 
application of antibiotics against vancomycin 
resistant Enterococcus faecium (VREF) would 
help designing methods for pathogens control. 
[49] Recently, there is no current therapy that 
consistently provides bactericidal activity for 
critical infections due to VRE.  The efficacy of 
therapy remains problematic because VRE is 
frequently related to violent underlying diseases 
and can be a part of polymicrobial infection. [50, 
51] 
Staphylococcus aureus 
     Nearly 25 - 30% of skin or noses of healthy 
people are colonized by Staphylococcus aureus. 
Methicillin-resistant S. aureus (MRSA) is 
resistant to certain antibiotics, such as methicillin, 
dicloxacillin, oxacillin, cloxacillin, nafcillin, and 
closely related class of drugs, such as 
cephalosporins. The use of more powerful drugs 
than necessary for less serious infections may be 
some of the causes of the MRSA expansion. 
MRSA isolates  which are susceptible only to 
glycopeptides antibiotics, such as vancomycin, 
are becoming multidrug-resistant. [52] Now, low 
level resistance to vancomycin is emerging and 
increasing .[53]  
The possible predisposing factors of MRSA 
emergence are: consumption of antibiotics 
without medical prescription, lack of awareness, 
receipt of antibiotics before coming to the 
hospital, long duration of hospitalization, etc. [54] 
Infected patients and health care providers’ 
carriers play a significant role in spreading and 
transferring this badbug in hospitals. [55] Studies 
on MRSA surveillance in hospitals and 
communities represent the main challenges of the 
healthcare setting .[56] Unfortunately,  penicillin 
resistant bacteria can spread in healthcare setting 
and in the community. Methicillin narrow 
spectrum semi-synthetic penicillin was introduced 
to overcome infections due to beta-lactamase-
producing S. aureus. Strains isolate from the 
hospital are  named as hospital acquired S. aureus  
(HASA). [57, 58]Clindamycin, a macrolide-
lincosamide-streptogramin B (MLSB) antibiotic, 
is a good substitute to treat these infections. 
Unfortunately,a diversity of erm genes, with 
either constitutively (MLSBc phenotype) or 
inducibely (MLSBi phenotype) expression can 
cause resistance to macrolide (MLSB). Active 
efflux pump, produced by msrA gene (MS 
phenotype), is another resistance mechanism. The 
treatment of  serious bacterial infections with 
clindamycin may result in failure, therefore 
detection of this resistance by D test (double disc 
diffusion test) is a  neccesity. Laboratory 
susceptibility test for clindamycin cannot detect  
routinely inducible clindamycin resistance and 
erythromycin resistant - clindamycin sensitive 
strains. [59, 60]Staphylococcus aureus causes 
atopic dermatitis (AD)  and induces skin 
inflammation by secreting superantigens 
following a chronic relapsing course and defects 
in innate and acquired immune response resulting 
in a heightened susceptibility to bacterial, viral 
and fungal infections .[61-67] The high rate of 
S.aureus colonization in the nasal cavity and skin 
lesions of AD patients has been reported, es-
pecially in ranges between 76–100%, compared to 
2–25% in healthy people .[68-70]It might be so 
that a combination of host factors containing skin 
barrier disorders and  impaired host immune 
responses in AD patients are the major factors in 
this respect.[71, 72]Oxacillin–resistant 
staphylococci are resistant to all beta-lactam 
antimicrobial drugs  except newer cephalosporins 
with anti-MRSA activity. Thus, susceptibility or 
resistance to a broad spectrum of beta-lactam 
drugs may be decreased due to susceptibility tests 
such as  penicillin, cefoxitin or oxacillin. Routine 
testing of other penicillins, cephems, beta-
lactam/beta-lactamase inhibitor combination, or 
carbapenems is not recommended.A forecast of 
the existance of mecA-related oxacillin resistance 
in S.aureus and S.lugdunensis, examination of 
either cefoxitin disk diffusion or cefoxitin MIC 
tests can be used. The cefoxitin disk diffusion test 
is preferred for the purpose of detecting of mecA-
mediated oxacillin resistance for coagulase –
negative staphylococci except S.lugdunensis. 
Cefoxitin is a substitute for tracing of oxacillin 
resistance, reporting oxacillin as susceptible or 
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resistant based on cefoxitin results. If a 
penicillinase –stable penicillin is examined, 
oxacillin is the preferred agent, and results can be 
used to the other penicillinase -stable penicillins, 
dicloxacillin, flucloxacillin and cloxacillin. [73] 
Klebsiella pneumonia 
     Klebsiella pneumonia belonged to the 
Enterobacteriaceae family that frequently causes 
lower respiratory tract infection and catheter-
associated urinary tract infection. 
Klebsiella pneumonia is progressively resistant to 
penicillin and ampicillin because of its beta-
lactamases. In addition, the bacterium belongs to 
the extended-spectrum beta-lactamase or ESBL 
strains and is increasingly multidrug-resistant to a 
wide spectrum such as cephalosporin or 
ceftazidim. [74] 
The emergence of Klebsiella pneumonia isolates 
producing carbapenemases (KPCs) has become a 
major obstacle in the last 5 years. 
Carbapenemases are able to destroy the 
carbapenems and cause resistance against a wide 
spectrum of antibiotics. [75-78] Recently, many 
areas in the world have been affected and KPC-
producing strains have now been detected from 
many countries  such as China, France, Norway, 
Brazil, Sweden, Scotland, Trinidad, Colombia, 
Poland and Tobago, Columbia, occupied 
Palestine, Greece and Puerto Rico. [79-89] KPC-1 
beta - lactamase was created because of a great 
plasmid that was responsible for the resistance  
carbapenems, extended-spectrum cephalosporins 
and aztreonam. [90,91]The fast propagation of 
bacterial resistance is perhaps due to the bla- KPC 
gene carriage on plasmids. Plasmid-mediated 
imipenem-hydrolyzing enzyme (KPC-2) among 
multiple carbapenem resistant bacteria is 
increasing. [92]  
Currently, a predominant isolate  and sequence 
type 258(ST258) is identified to cause about  70% 
of K. pneumoniae infections .[93]It is forecasted 
that resistance due to KPC will be a mechanism of 
multidrug-resistance in Gram-negative bacilli in 
the nearby future. [94,95]The increasing interest 
on combination therapy for K. pneumoniae 
infections is due to its ability to obtain resistance 
to distinct classes of antibiotics, containing  
carbapenems, with limited accessibility of 
impressive agents. The increasing rate and high 
mortality of infections have prompted 
physicians to consumption combination therapy 
even more often for the handling of infections 
because of such bacteria. [96] 
Acinetobacter baumannii 
     Acinetobacter baumannii is an opportunistic 
bacterial pathogen with the power of causing 
hospital acquired infections, individually in 
intensive care units, urinary tract infection, 
bacteremia, meningitis, pneumonia, wound 
infections, healthcare-related infections (HAIs)  
with myltiple outbreaks. [97-102] 
 From  January 2002 to August 2004, 
bloodstream infections due to A. baumannii were 
detected among 85 soldiers in Afghanistan and 
the Iraq/Kuwait area. A total of 35 % of the 
strains were susceptible to just one class of 
antibiotics and 4 % were resistance to all 
standard drugs.[103] The epidemic potential and 
the clinical severity of A. baumannii infections 
are primarily related to the capability to survive 
and propagation in healthcare setting  and to 
expand resistance to a diversity of antimicrobial 
agents, containing  fluoroquinolones, broad-
spectrum beta-lactams, and carbapenems.[107-
109]  
Antimicrobial resistance causes major limits to 
treatment options in infected patients, particularly 
in isolates with carbapenems resistant. Other 
therapeutic options contain aminoglycosides, 
sulbactam, tigecycline, and polymixyns. 
[110,111]  Spread  of A. baumannii  in  a  hospital 
setting is facilitated both by tolerance to 
desiccation and development of bacterial 
resistance through antibiotic selective pressure. 
[112]  Antimicrobial resistance causes major 
limits to the choice of antibiotics in patients  
infected by carbapenems resistant 
isolates.[113]MDR  A.baumannii is resistant to 3 
or more several classes of antibiotics containing 
beta-lactams, aminoglycosides, fluoroquinolones, 
and 3rd generation of cephalosporin .[114] Pan-
drug resistance (PDR) A.baumannii was described 
as the strains that were resistant to all examined 
antibiotics exclude colistin and tigecycline .[115] 
Pseudomonas aeruginosa  
     One of gram negative bacteria that  has intrinsic 
resistance characteristic  is Pseudomonas aeruginosa. 
Low antibiotic susceptibility in this bacteria is due 
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to low penetrance of the bacterial cellular 
envelopes, function of multidrug efflux pumps, 
mutations in targets of antibiotics and the 
horizontal gene transfer of antibiotic resistance 
determinants. [116-120] 
The outcomes of infection caused by MDR 
Pseudomonas may be related to enlarge 
morbidity and mortality, which can cause narrow 
effective antimicrobial choices as resistance to at 
least three classes of antibiotics, mainly 
carbapenems, antipseudomonal penicillins, 
cephalosporins, aminoglycosides, and 
fluoroquinolones. [120-122] 
One of the most common lethal genetic diseases 
due to Pseudomonas aeruginosa in the white 
population is cystic fibrosis (CF), with the 
prevalence of 1 case per 90,000 in Asia .[123-
125] 
 If this disorder is almost treated, the average 
prospects of life expectanye of CF patients would 
increase more than 35 to even 50 years. [126] P. 
aeruginosa that infects CF patients has serious 
implications for infection control in the hospital 
.[127] 
Wide range of antimicrobial resistances in MDR 
P. aeruginosa mainly cause the dose limits for 
remediation such as polymixyns and 
aminoglycosides. Recent studies have reported 
that these agents may or may not be as efficient 
as first-line drugs; and yet, they may also be 
related to more serious detrimental effects (such 
as neurotoxicity, ototoxicity and nephrotoxicity). 
[128-137]  
P. aeruginosa is the most studied pathogen about 
the priority of combination diet over 
monotherapy. [138-140] Other prospective 
studies and meta-analysis have been unsuccessful 
to demonstrate the priority of the combination 
therapy versus monotherapy for the treatment of 
P. aeruginosa infections. [141–143] 
Serious infections such as burn wounds due to by 
Pseudomonas aeruginosa are treated through the 
combination of a beta-lactam drugs and an 
aminoglycoside. The emergance of MDR in 
Pseudomonas aeruginosa containing resistance 
to β-lactams, aminoglycosides, and 
fluoroquinolones is extremely problematic to the 
treatment of burn patient. So, the recognition of 
drug resistance patterns in P. aeruginosa and 
tracing of pan-resistant producing bacteria are of 
major importance in prevention and control of 
infections in burn center ward. [144] 
Enterobacter spp. 
     Enterobacter spp. is significantly responsible 
for some  important nosocomial infections, 
representing wide MDR through plasmid-
encoded ESBLs and KPC 
carbapenemases,metallo-β-lactamase, even  OXA 
and metallo-β-lactamase-1. Although few 
antimicrobials such as colistin and tigecycline are 
influenced by these resistant bacteria and also 
against many of the other ESKAPE pathogens, 
there is little or no drugs in the 'pipeline', being 
remarkably effective in addressing this mounting 
health crisis.[6,145-146] In veterinary medicine, 
fluoroquinolone resistance is becoming more 
common. This Resistance is caused by both  
chromosomal and plasmid-mediated 
fluoroquinolone resistance (PMQR) mechanisms 
which are co-located with other antimicrobial 
resistance genes including β-lactamases.  The 
genes’ relationship with PMQR can cause 
resistance to fluoroquinolone when joined with 
topoisomerase mutations and efflux. [147] 
In some situations, examination of subsequent 
strains to find resistance that may have expanded 
might be warranted before three to four days. The 
decisions to do so require knowledge of particular 
condition and the intensity of patient condition 
such as Enterobacter cloacae isolated from a 
blood culture of premature infants. CLSI protocol  
to carry out susceptibility experiment on repeat 
isolates should be defined after negotiation with 
medical personnel. Some strains of Citrobacter, 
Providencia and Enterobacter spp. have been 
presented to give false-susceptible outcomes 
when tested by disk diffusion with cefdinir and 
loracaebef strains of these genera should not be 
examined by disk diffusion with agents. [71] 
 
DISCUSSION 
     Health crisis of ESKAPE pathogens seems 
overwhelming. There are comprehensive 
guidelines for antibiotic resistance control and for 
a coordinated holistic medicine  to uniform 
industrial and governmental organizations.[4,148-
151]In the short run, with treatment options 
diminishing, it is necessary that the last remaining 
 
Journal of Paramedical Sciences (JPS)                Summer2016 Vol 7, No3. ISSN 2008-4978 
48 
 
antimicrobial agents be protected via intellectual 
choice and ameliorated infection control. The call 
for antibiotic superintendence has been mentioned 
for several years by health authorities to temper 
the expansion of resistance mechanisms versus 
the recent persisted antimicrobial agents. [152-
154]  
Selection of suitable guidelines is readily 
accessible and accurate prescribing protocols have 
been successfully implemented  worldwide. 
[155]Prescription of the most suitable 
antimicrobial agents at the right dose and period, 
and for an appropriate time has consistently 
improved sick people outcomes and has decreased 
antibiotic resistance appearance. [156-157]The 
campaign of "Clean your hands” in the UK 
displayed how public intermediation for control 
of infection one behind another follow with a high 
profile governmental force can decrease selected 
HAIs (healthcare-related infections). [158] 
In the same case, common notification 
campaigns, such as the European Antibiotics 
Awareness Day (EAAD) can support and 
emphasize the foundation sequences of 
consecutive antibiotic abusage in both medical 
profession and in agronomy by the suitable 
political and financial patronage as the crisis 
expands and common knowledge enhances. [159] 
Louis Pasteur’s and Robert Koch’s pioneering 
methodologies appointed the arena of classical 
microbiology and organized the basis of 
antimicrobial susceptibility examination over 150 
years ago till now. [71,160] However, some 
microbiologists suggest more complex biofilm 
manner  in distinction for the more lightly 
reproducible planktonic manner which has 
mislead research generations .[161,162] Bacterial 
biofilms provide a distinguished survival benefit 
versus antimicrobial agents in comparison with  
their planktonic counterparts, by a 1000-times 
augmentation in some agents concentration 
Biofilm development is the underlying basis for 
persistent HAIs related to installing medical 
devices in the greater numbers, made possible by 
ESKAPE pathogens.[163-167]Based on standard 
guidelines to make proper and practical antibiotic 
susceptibility testing, the number of agents 
examined should be confined. CLSI have lists of 
those agents that perform the fundamental 
prescriptions for routine utilization in most 
clinical laboratories. The tables have columns 
based on particular organisms or organism 
groups; several antibiotics are recommended in 
preference for experiment to help laboratories in 
their conventional testing batteries selection.  This 
means that major errors are less than 3% and 
minor errors are fewer than 10%, based on an 
examination of great collection of accidental 
clinical strains. Moreover, to determine for an “or 
word in report of antibiotic susceptibility testing, 
at least 100 strains with resistance to the agents in 
question must be examined, and a result of 
“resistant” must be gained with all agents for at 
least 95% of the strains.[149]  
To sum up, it can be said that healthcare-
associated, community-acquired, and nosocomial 
infections should be carefully considered . In this 
review, the alarming frequency and increasing 
tendency of extremely resistant ESKAPE 
pathogens in the worldwide is highlighted. The 
awareness of residential antimicrobial resistance 
can support the selection of a convenient 
empirical therapeutic diet in which diseases occur 
due to ESKAPE pathogens. [168] 
It should be mentioned that the clinical response 
of a patient after  receiving  antibiotic does not 
always correlate with the laboratory reports. Even 
so, it should be noted that description of 
pathogens antimicrobial resistance patterns needs 
a consecutive update. [128] We must increase 
hospital infection-control practices for the 
purpose of restricting the spread of resistance. 
This procedure will ensure a steady stream of 
newantibacterials to meet the needs of current patients . 
“The authors declare no conflict of interest” 
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